Guideline Recommendations for Management of Vaginitis

Bacterial Vaginosis – Non‑Pregnant Women

• The CDC lists three equivalent first‑line regimens: oral metronidazole 500 mg twice daily for 7 days (≈95 % cure), metronidazole 0.75 % vaginal gel once daily for 5 days (comparable efficacy), and clindamycin 2 % intravaginal cream nightly for 7 days (slightly lower efficacy) 1.
• A single oral dose of metronidazole 2 g yields a lower cure rate (~84 % vs ≈95 % with the 7‑day regimen) and should not be used as first‑line therapy 2.
• Patients must avoid alcohol during metronidazole therapy and for 24 h after the last dose to prevent disulfiram‑like reactions (flushing, nausea, vomiting, headache) 1.
• Clindamycin cream and ovules are oil‑based and can degrade latex condoms and diaphragms, potentially reducing contraceptive effectiveness 1.
• For patients with metronidazole allergy or intolerance, oral clindamycin 300 mg twice daily for 7 days is the preferred alternative 3.
• Vaginal metronidazole formulations must not be given to patients allergic to oral metronidazole because cross‑reactivity can cause severe reactions 3.
• Routine follow‑up visits are unnecessary if symptoms resolve after therapy; patients should return only if symptoms recur 3.
• Recurrence of bacterial vaginosis is common, occurring in 50–80 % of women within one year after successful treatment 1.
• The CDC does not recommend routine treatment of sexual partners for bacterial vaginosis, as partner therapy does not improve cure rates or reduce recurrence 3.

Bacterial Vaginosis – Pregnancy

• All symptomatic pregnant women should be treated for bacterial vaginosis because it is associated with preterm rupture of membranes, preterm labor, preterm birth, chorioamnionitis, postpartum endometritis, and post‑cesarean wound infection 3.
• High‑risk pregnant women (history of prior preterm delivery) should be screened and, if asymptomatic, treated early in the second trimester with metronidazole 250 mg orally three times daily for 7 days; alternatives include a single 2 g oral dose of metronidazole or clindamycin 300 mg orally twice daily for 7 days 2.
• Low‑risk pregnant women (no prior preterm delivery) should receive metronidazole 250 mg orally three times daily for 7 days to treat symptomatic infection; alternatives include a single 2 g oral dose of metronidazole, clindamycin 300 mg orally twice daily for 7 days, or metronidazole 0.75 % vaginal gel twice daily for 5 days 2.
• Lower doses of metronidazole are recommended during pregnancy to minimize fetal exposure while maintaining efficacy 2.
• Clindamycin vaginal cream should be avoided in pregnancy because randomized trials have shown an increased risk of preterm delivery and neonatal infections 3.
• Current evidence indicates no consistent teratogenic or mutagenic risk associated with metronidazole use in pregnancy 1.
• Data on the safety and efficacy of metronidazole vaginal gel during pregnancy remain limited, and its use should be considered only when systemic therapy is contraindicated 2.

Vulvovaginal Candidiasis (VVC)

• For uncomplicated VVC in non‑pregnant women, topical azole agents (e.g., clotrimazole, miconazole, terconazole) and a single oral dose of fluconazole 150 mg are equally effective, according to IDSA recommendations 4.
• In recurrent VVC (≥4 episodes per year), an extended course of a topical azole for 7–14 days or two doses of fluconazole 150 mg given 72 hours apart is recommended for initial therapy; weekly fluconazole maintenance for up to 6 months improves treatment success 4.
• Non‑albicans Candida species (e.g., C. glabrata, C. krusei) often exhibit reduced susceptibility to azoles; topical boric acid or topical flucytosine are frequently effective alternatives 4.

Trichomoniasis

• The CDC recommends metronidazole 2 g orally as a single dose as the first‑line regimen for trichomoniasis, achieving cure rates of 90–95 % 2.
• An alternative regimen of metronidazole 500 mg orally twice daily for 7 days provides equivalent efficacy and may be used when a single dose is not feasible 2.
• If initial therapy fails, retreat with metronidazole 500 mg twice daily for 7 days; for repeated failures, a regimen of metronidazole 2 g orally once daily for 3–5 days is advised 2.
• For culture‑documented infections unresponsive to standard regimens, consultation with an infectious‑disease specialist and susceptibility testing are recommended 5.
• Sexual partners must be treated concurrently with the same metronidazole regimen; patients should abstain from intercourse until both patient and partner have completed therapy and are asymptomatic, which enhances overall cure rates 5.
• In pregnant women, metronidazole 2 g orally as a single dose after the first trimester is recommended; earlier trimesters were previously contraindicated but this restriction has been lifted based on safety data 5.
• Routine test‑of‑cure is not recommended for asymptomatic patients after treatment 5.

Special Populations

• HIV‑infected patients with bacterial vaginosis or trichomoniasis should receive the same treatment regimens as HIV‑negative patients, per CDC guidance 2.
• Administration of metronidazole for bacterial vaginosis before surgical abortion markedly reduces the incidence of post‑abortion pelvic inflammatory disease 1.
• In refractory cases where standard therapy and partner treatment have failed, referral to an infectious‑disease specialist or experienced gynecologist for susceptibility testing and alternative regimens is advised 1.